Type: Public
On the web: http://www.elan.com
Employees: 1,219
Employee growth: (7.7%)

Elan has brain and nerve conditions on its mind. The biotech company is focused on the development of pharmaceuticals for neurological and autoimmune disorders. Its product offerings include anti-infectives and treatments for degenerative diseases. Elan's future fortunes rely largely on the success of beleaguered multiple sclerosis (MS) and Crohn's disease therapy Tysabri, a monoclonal antibody (single-source protein) therapy it co-developed with Biogen Idec. Elan's pipeline of potential future releases includes new drugs for the treatment of Alzheimer's disease and Parkinson's disease.

Key numbers for fiscal year ending December, 2010:
Sales: $1,169.7M
One year growth: 5.1%
Net income: ($324.7)M

Officers:
Chairman: Robert A. (Bob) Ingram
CEO and Director: G. Kelly Martin
President: Carlos V. Paya

Competitors:
Bayer HealthCare Pharmaceuticals
Biogen Idec
Pfizer

© 2012 Hoover's, Inc. All rights reserved.